Crossmark

Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

Crossref DOI link: https://doi.org/10.1186/s12894-016-0164-4

Published Online: 2016-08-02

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karunasinghe, Nishi http://orcid.org/0000-0002-6383-4163
Zhu, Yifei

Han, Dug Yeo

Lange, Katja

Zhu, Shuotun

Wang, Alice

Ellett, Stephanie

Masters, Jonathan

Goudie, Megan

Keogh, Justin

Benjamin, Benji

Holmes, Michael

Ferguson, Lynnette R.
Funding

Funding for this research was provided by:

Cancer Society of New Zealand (Grant No. 10/08)

Mad Butcher’s Charitable Trust, New Zealand

A+ Trust Auckland District Health Board (Grant No. 5461-PG-1204-007)

GoodFellow Trust, Urology Department, Auckland Hospital (Grant No. +3192)

Auckland Cancer Society, New Zealand
License Information

License valid from 2016-08-02

Document is current

Any future updates will be listed below